Overview

Study to Examine Safety, Tolerability, and Effect on Body Weight of Metreleptin Administered in Conjunction With Pramlintide in Obese and Overweight Subjects

Status:
Completed

Trial end date:
2009-10-01

Target enrollment:

Participant gender:

Summary

A randomized, double-blind, placebo-controlled, dose-ranging study to examine the safety, tolerability and effect on body weight of a range of doses of metreleptin and pramlintide, each administered by a separate subcutaneous (SC) injection in obese and overweight subjects.

Phase:

Phase 2

Details

Lead Sponsor:

AstraZeneca

Treatments:

Islet Amyloid Polypeptide
Pramlintide